In this episode, Martin reveals his full trading record, showing how he achieved a 477% gain and the key moves behind his performance. He explains why he’s now all in on Biohaven stock and reviews IONQ’s latest earnings, highlighting what the results mean for the broader tech and biotech markets.

In this episode, Martin breaks down his trading approach to Sarepta and reviews the latest earnings reports from AMD and Super Micro Computer (SMCI). He shares his candid opinions on Michael Burry’s market views and concludes with an in-depth review of Amgen (AMGN) stock.

In this episode, Martin explains why he believes making money in a bear market can be straightforward with the right strategy. He shares his latest forecast for QURE, discusses his ongoing trades in Sarepta, and provides updated thoughts on Palantir’s performance and valuation.

In this episode, Martin examines how a single FDA-related hint caused QURE stock to surge and what it reveals about market sensitivity to biotech news. He also discusses his outlook on SPRB, speculating on when it could reach the $500 mark, and provides analysis of Uniqure and UnitedHealth stocks within the broader healthcare landscape.

In this episode, Martin shares that Sarepta has grown to represent 40% of his portfolio and explains the reasoning behind his conviction. He discusses the recent crash in QURE stock, provides an updated forecast for Biohaven, and analyzes what he views as an emerging bubble in Palantir.

In this episode, Martin analyzes Walmart’s valuation and explains why he believes it signals a broader market shift toward caution and liquidity. He also reviews Reddit’s recent earnings, interpreting them as a warning sign for speculative stocks and overvalued growth plays.

In this episode, Martin examines Berkshire Hathaway’s record $382 billion cash position and what it signals about market sentiment and opportunity. Through a compilation of key investing insights from recent streams, he shares the lessons and “gems” he believes are most relevant for navigating today’s uncertain environment.

In this episode, Martin reveals which meme stock he’s currently long on and explains the reasoning behind the position. He also provides an analysis of Taiwan Semiconductor, discusses recent developments with Tesla and Apple, and ties these insights into his broader market strategy.

In this episode, Martin reflects on growing market uncertainty and the idea that “nothing is safe anymore.” He highlights why he sees Biohaven as having 3x potential, conducts a detailed analysis of Berkshire Hathaway’s stock, and shares updated perspectives on Apple and Meta within the broader market context.

In this episode, Martin evaluates whether Meta has become a clear buying opportunity at its current valuation. He compares Meta’s positioning to Google, Apple, and Nvidia, offering his stock forecasts for each and outlining the key factors driving his outlook on big tech performance.